Aktie A2APCZ MADRIGAL PHARMACEUTICALS, INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Madrigal Pharmaceuticals, Inc.

Aktien

A2APCZ

US5588681057

MDGL

Markt geschlossen - Nasdaq
Andere Börsenplätze
 22:00:00 24.05.2024 		% 5 Tage % 1. Jan.
229,6 USD -2,24 % Intraday Chart für Madrigal Pharmaceuticals, Inc. +4,33 % -0,78 %
17.05. Madrigal Pharmaceuticals Insider verkaufte Aktien im Wert von $4.787.404, laut einer aktuellen SEC Einreichung MT
10.05. MADRIGAL PHARMACEUTICALS, INC. : B. Riley gibt neutrale Bewertung ab ZM

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Certain Common Stock of Madrigal Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 19-MAY-2024.
Certain Warrants of Madrigal Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 19-MAY-2024.
Certain Pre Funded Warrants of Madrigal Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 19-MAY-2024.
Certain Performance Stock Units of Madrigal Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 19-MAY-2024.
Certain Restricted Stock Units of Madrigal Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 19-MAY-2024.
Certain Options of Madrigal Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 19-MAY-2024.
Madrigal Pharmaceuticals Insider Sold Shares Worth $4,787,404, According to a Recent SEC Filing
Sector Update: Health Care Stocks Steady Pre-Bell Tuesday
Madrigal Pharmaceuticals Q1 Loss Widens; Shares Fall Pre-Bell
Madrigal: Q1 Earnings Snapshot
Madrigal Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates
Madrigal Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Nonalcoholic Steatohepatitis Market to Observe Impressive Growth During the Forecast Period | Inventiva Pharma, Zydus Therapeutics, Novo Nordisk A/S, Eli Lilly and Company, Madrigal Pharmaceuticals
Madrigal Statement on the Passing of Dr. Stephen Harrison
Madrigal Pharmaceuticals to Release First-Quarter 2024 Financial Results and Host Webcast on May 7, 2024
Madrigal Pharmaceuticals to Release First-Quarter 2024 Financial Results and Host Webcast on May 7, 2024
6 Stocks Positioned to Soar as Investors Focus on MASH
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Madrigal Pharmaceuticals Insider Sold Shares Worth $658,258, According to a Recent SEC Filing
Madrigal Pharmaceuticals Insider Sold Shares Worth $6,467,491, According to a Recent SEC Filing
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A2APCZ Aktie
  4. Nachrichten Madrigal Pharmaceuticals, Inc.
  5. Andere Sprachen